Dtsch Med Wochenschr 2012; 137(27): 1409-1420
DOI: 10.1055/s-0032-1305058
CME | Review article
Nephrologie
© Georg Thieme Verlag KG Stuttgart · New York

Diagnostik, Bedeutung, Prävention und Therapie einer Mikroalbuminurie

Diagnosis, implication, prevention and treatment of microalbuminuria
R. E. Schmieder
1   Medizinische Klinik 4 der Universität Erlangen-Nürnberg
,
P. Bramlage
2   Institut für Pharmakologie und präventive Medizin, Mahlow
› Author Affiliations
Further Information

Publication History

12 January 2012

08 March 2012

Publication Date:
26 June 2012 (online)

 
  • Literatur

  • 1 Afshinnia F, Wilt TJ, Duval S et al. Weight loss and proteinuria: systematic review of clinical trials and comparative cohorts. Nephrol Dial Transplant 2010; 25: 1173-1183
  • 2 Almeida JC, Zelmanovitz T, Vaz JS et al. Sources of protein and polyunsaturated fatty acids of the diet and microalbuminuria in type 2 diabetes mellitus. J Am Coll Nutr 2008; 27: 528-537
  • 3 Arnlov J, Evans JC, Meigs JB et al. Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study. Circulation 2005; 112: 969-975
  • 4 Barnett AH, Bain SC, Bouter P et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004; 351: 1952-1961
  • 5 Bilous R, Chaturvedi N, Sjolie AK et al. Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials. Ann Intern Med 2009; 151: 11-20, W13-14
  • 6 Bohm M, Thoenes M, Danchin N et al. Association of cardiovascular risk factors with microalbuminuria in hypertensive individuals: the i-SEARCH global study. J Hypertens 2007; 25: 2317-2324
  • 7 Bramlage P, Pittrow D, Lehnert H et al. Frequency of albuminuria in primary care: a cross-sectional study. Eur J Cardiovasc Prev Rehabil 2007; 14: 107-113
  • 8 Deckert T, Feldt-Rasmussen B, Borch-Johnsen K et al. Albuminuria reflects widespread vascular damage. The Steno hypothesis. Diabetologia 1989; 32: 219-226
  • 9 EUCLID Study Group. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet 1997; 349: 1787-1792
  • 10 Gaede P, Lund-Andersen H, Parving HH et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008; 358: 580-591
  • 11 Gerstein HC, Mann JF, Yi Q et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001; 286: 421-426
  • 12 Haller H, Ito S, Izzo JL Jr et al. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 2011; 364: 907-917
  • 13 Hasslacher C, Wolf G, Kempe P et al. Diabetische Nephropathie. Diabetologie 2011; 6: 111-S114
  • 14 Hillege HL, Fidler V, Diercks GF et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002; 106: 1777-1782
  • 15 Hillege HL, Janssen WM, Bak AA et al. Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity. J Intern Med 2001; 249: 519-526
  • 16 Ibsen H, Olsen MH, Wachtell K et al. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension 2005; 45: 198-202
  • 17 Jones CA, Francis ME, Eberhardt MS et al. Microalbuminuria in the US population: third National Health and Nutrition Examination Survey. Am J Kidney Dis 2002; 39: 445-459
  • 18 Mathiesen ER, Ronn B, Jensen T et al. Relationship between blood pressure and urinary albumin excretion in development of microalbuminuria. Diabetes 1990; 39: 245-249
  • 19 Mauer M, Zinman B, Gardiner R et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med 2009; 361: 40-51
  • 20 National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39: 1-266
  • 21 Parving HH, Lehnert H, Brochner-Mortensen J et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-878
  • 22 Parving HH, Lewis JB, Ravid M et al. Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective. Kidney Int 2006; 69: 2057-2063
  • 23 Ritz E, Viberti GC, Ruilope LM et al. Determinants of urinary albumin excretion within the normal range in patients with type 2 diabetes: the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study. Diabetologia 2010; 53: 49-57
  • 24 Ruggenenti P, Fassi A, Ilieva AP et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004; 351: 1941-1951
  • 25 Sarnak MJ, Levey AS, Schoolwerth AC et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003; 108: 2154-2169
  • 26 Scheid DC, McCarthy LH, Lawler FH et al. Screening for microalbuminuria to prevent nephropathy in patients with diabetes: a systematic review of the evidence. J Fam Pract 2001; 50: 661-668
  • 27 Schmieder RE, Mann JF, Schumacher H et al. Changes in albuminuria predict mortality and morbidity in patients with vascular disease. J Am Soc Nephrol 2011; 22: 1353-1364
  • 28 Schmieder RE, Schrader J, Zidek W et al. Low-grade albuminuria and cardiovascular risk: What is the evidence?. Clin Res Cardiol 2007; 96: 247-257
  • 29 Schrader J, Luders S, Kulschewski A et al. Microalbuminuria and tubular proteinuria as risk predictors of cardiovascular morbidity and mortality in essential hypertension: final results of a prospective long-term study (MARPLE Study)*. J Hypertens 2006; 24: 541-548
  • 30 Thoenes M, Reil JC, Khan BV et al. Abdominal obesity is associated with microalbuminuria and an elevated cardiovascular risk profile in patients with hypertension. Vasc Health Risk Manag 2009; 5: 577-585
  • 31 Thomas MC, Atkins RC. Blood pressure lowering for the prevention and treatment of diabetic kidney disease. Drugs 2006; 66: 2213-2234
  • 32 Voulgari C, Katsilambros N, Tentolouris N. Smoking cessation predicts amelioration of microalbuminuria in newly diagnosed type 2 diabetes mellitus: a 1-year prospective study. Metabolism 2011; 60: 1456-1464
  • 33 Yamaji T, Fukuhara T, Kinoshita M. Increased capillary permeability to albumin in diabetic rat myocardium. Circ Res 1993; 72: 947-957